$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000148381313000085 Filed on August 07, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$16.01M	$14.45M	$7.757M
YoY Change	200.19%	86.33%	-66.55%
Cost Of Revenue	$683.0K	$1.284M	$143.1K
YoY Change	201.37%	797.15%	-28.44%
Gross Profit	$9.342M	$1.816M	$381.8K
YoY Change	1811.53%	375.61%	-98.34%
Gross Profit Margin	58.34%	12.56%	4.92%
Selling, General & Admin	$8.135M	$7.300M	$5.580M
YoY Change	44.39%	30.81%	21.31%
% of Gross Profit	87.08%	401.98%	1461.53%
Research & Development	$25.69M	$27.99M	$16.08M
YoY Change	31.71%	74.05%	5.11%
% of Gross Profit	274.98%	1541.35%	4211.84%
Depreciation & Amortization	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit	3.21%	16.52%	78.57%
Operating Expenses	$33.82M	$35.29M	$21.66M
YoY Change	34.56%	62.92%	8.86%
Operating Profit	-$18.49M	-$22.12M	-$14.05M
YoY Change	-7.67%	57.47%	-553.16%
Interest Expense	$850.0K	$849.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$52.00K	$58.00K	$26.98K
YoY Change	116.75%	114.98%
Pretax Income	-$19.30M	-$22.90M	-$14.00M
YoY Change	-3.5%	63.57%	-551.61%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$19.29M	-$22.91M	-$14.02M
YoY Change	-3.57%	63.41%	-549.93%
Net Earnings / Revenue	-120.48%	-158.52%	-180.75%
Basic Earnings Per Share
Diluted Earnings Per Share	-$171.1K	-$203.6K	-$124.9K
COMMON SHARES
Basic Shares Outstanding	113.3M shares	113.2M shares	112.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.30M	$76.00M	$102.0M
YoY Change	-25.46%	-25.49%	28.95%
Cash & Equivalents	$17.49M	$27.93M	$102.0M
Short-Term Investments	$47.80M	$48.10M
Other Short-Term Assets	$9.100M	$11.10M	$10.20M
YoY Change	-20.18%	8.82%	137.21%
Inventory	$3.846M	$2.467M	$1.800M
Prepaid Expenses
Receivables	$24.52M	$10.83M	$5.700M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$102.8M	$100.4M	$119.7M
YoY Change	-2.63%	-16.11%	36.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.936M	$4.577M	$2.000M
YoY Change	105.66%	128.83%	33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.400M	$2.400M
YoY Change
Total Long-Term Assets	$7.327M	$6.966M	$2.000M
YoY Change	205.3%	248.32%	33.33%
TOTAL ASSETS
Total Short-Term Assets	$102.8M	$100.4M	$119.7M
Total Long-Term Assets	$7.327M	$6.966M	$2.000M
Total Assets	$110.1M	$107.4M	$121.7M
YoY Change	1.99%	-11.76%	35.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.592M	$7.481M	$2.100M
YoY Change	59.76%	256.24%	23.53%
Accrued Expenses	$20.62M	$15.29M	$7.500M
YoY Change	157.81%	103.86%	-21.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.970M	$3.643M
YoY Change
Total Short-Term Liabilities	$39.62M	$32.83M	$16.10M
YoY Change	88.68%	103.93%	-48.89%
LONG-TERM LIABILITIES
Long-Term Debt	$26.30M	$28.20M	$0.00
YoY Change
Other Long-Term Liabilities	$921.5K	$678.7K	$36.40M
YoY Change	-97.43%	-98.14%	-3.96%
Total Long-Term Liabilities	$921.5K	$678.7K	$36.40M
YoY Change	-97.43%	-98.14%	-3.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.62M	$32.83M	$16.10M
Total Long-Term Liabilities	$921.5K	$678.7K	$36.40M
Total Liabilities	$40.55M	$33.51M	$52.50M
YoY Change	-28.62%	-36.17%	-24.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$360.1M	-$340.8M
YoY Change
Common Stock	$356.6M	$352.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.486M	$11.14M	$69.20M
YoY Change
Total Liabilities & Shareholders Equity	$110.1M	$107.4M	$121.7M
YoY Change	1.99%	-11.76%	35.98%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$19.29M	-$22.91M	-$14.02M
YoY Change	-3.57%	63.41%	-549.93%
Depreciation, Depletion And Amortization	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$12.40M	-$10.90M	-$13.70M
YoY Change	-13.29%	-20.44%	-470.27%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$100.0K	-$700.0K
YoY Change	50.0%	-85.71%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$300.0K	-$100.0K	-$700.0K
YoY Change	50.0%	-85.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.300M	0.000	-100.0K
YoY Change	2200.0%	-100.0%	-106.67%
NET CHANGE
Cash From Operating Activities	-12.40M	-10.90M	-13.70M
Cash From Investing Activities	-300.0K	-100.0K	-700.0K
Cash From Financing Activities	2.300M	0.000	-100.0K
Net Change In Cash	-10.40M	-11.00M	-14.50M
YoY Change	-27.78%	-24.14%	-378.85%
FREE CASH FLOW
Cash From Operating Activities	-$12.40M	-$10.90M	-$13.70M
Capital Expenditures	-$300.0K	-$100.0K	-$700.0K
Free Cash Flow	-$12.10M	-$10.80M	-$13.00M
YoY Change	-14.18%	-16.92%	-451.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1599	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-53740	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1886226	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7480982	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2271689	USD
CY2012Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	15881227	USD
CY2013Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	11026667	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10831828	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15703087	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-497323	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7783447	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15289431	USD
CY2012Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2223242	USD
CY2013Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	10003869	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6680627	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7037944	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-39309	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	347314658	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	351843228	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2285052	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4439980	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2439649	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4836336	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	752816	USD
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9200000	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7300000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7300000	shares
CY2013Q2	us-gaap	Assets Assets	107387338	USD
CY2012Q4	us-gaap	Assets Assets	134728397	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	100420847	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	130627935	USD
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	98024269	USD
CY2013Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	70203104	USD
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	48121945	USD
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	0	USD
CY2013Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	48082636	USD
CY2013Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3100000	USD
CY2013Q2	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	48082636	USD
CY2013Q2	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	40205	USD
CY2013Q2	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	896	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	43119	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	203464	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	650000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1450000	USD
CY2013Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	2100000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99501264	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27927551	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52825527	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102041617	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	49216090	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-71573713	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112709174	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	113285582	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	113285582	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112709174	shares
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	113286	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	112709	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14021119	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22921689	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42239189	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29140300	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2022920	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	213881	USD
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1283949	USD
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	143120	USD
	us-gaap	Costs And Expenses CostsAndExpenses	44385850	USD
	us-gaap	Costs And Expenses CostsAndExpenses	66903771	USD
CY2012Q2	us-gaap	Costs And Expenses CostsAndExpenses	21805273	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	36574458	USD
CY2013Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	874208	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	861879	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	43845983	USD
CY2013Q2	us-gaap	Deferred Revenue DeferredRevenue	40101677	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-203697	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6419681	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8891017	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	33681996	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	34954966	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	297000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	510000	USD
CY2012Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	272000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	592000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	509995	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	591700	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3304345	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4053590	USD
CY2013Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6988	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12530088	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3601463	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3424631	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4871259	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1153795	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3744306	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1216631	USD
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	59686	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	848995	USD
	us-gaap	Interest Expense InterestExpense	1696579	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	0	USD
CY2013Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	849000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	1700000	USD
	us-gaap	Interest Paid InterestPaid	963188	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	751378	USD
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1154987	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	2466999	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	2670696	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1127061	USD
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1049727	USD
CY2013Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	262285	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	792257	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134728397	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107387338	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	32833250	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18946153	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	14485001	USD
CY2012Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	7232233	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	21678903	USD
CY2013Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	11353957	USD
CY2013Q2	us-gaap	Long Term Debt LongTermDebt	26075507	USD
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	29661680	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	3643156	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a science-driven, biopharmaceutical company committed to making molecules into medicines for patients in need. Our research focuses primarily on human enzymes that alter the extracellular matrix. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, thus enhancing the efficacy and the convenience of other drugs or to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, such as diabetes, oncology and dermatology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of the product candidates in our current pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We have one proprietary commercial product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant. Our proprietary pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. We currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Pfizer Inc. (“Pfizer”), Baxter Healthcare Corporation (“Baxter”), ViroPharma Incorporated (“ViroPharma”), and Intrexon Corporation (“Intrexon”), with one approved product in Europe, one product candidate which has been submitted for regulatory approval in the U.S. and two product candidates which have been submitted for regulatory approval in Europe as well as several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were founded in 1998 and reincorporated from the State of Nevada to the State of Delaware in November 2007. Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these Notes to Condensed Consolidated Financial Statements refers to Halozyme Therapeutics, Inc. and our wholly-owned subsidiary, Halozyme, Inc.</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-307189	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83034522	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-705649	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49560896	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21705628	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33112783	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-14021119	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42199880	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29140300	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-22911511	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40616421	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29188496	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22120648	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14048098	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1506615	USD
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1981217	USD
CY2012Q4	us-gaap	Other Assets OtherAssets	74944	USD
CY2013Q2	us-gaap	Other Assets OtherAssets	442432	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-39309	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10178	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	678700	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48196	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26979	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	58132	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	113120	USD
CY2012Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2250791	USD
CY2013Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1378590	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	347282	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	373785	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	48946616	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	614280	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	705649	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	12752888	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	13001818	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12752888	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11111833	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	0	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1889985	USD
	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	400000	USD
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2013Q2	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81476845	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81500000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	66596	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1904959	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11614450	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10381089	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4576506	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3700462	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50025192	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31972838	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27990755	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16081729	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-340773528	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-298573648	USD
CY2013Q2	us-gaap	Revenues Revenues	14453810	USD
CY2012Q2	us-gaap	Revenues Revenues	7757175	USD
	us-gaap	Revenues Revenues	26287350	USD
	us-gaap	Revenues Revenues	15197354	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4608447	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	712353	USD
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	524942	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3099853	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12199131	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7299754	USD
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5580424	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14855659	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4836336	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4439980	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	6500000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7100000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9200000	shares
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7820000	shares
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	11143677	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	48853719	USD
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112063665	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	109826589	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112451693	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112486211	shares
CY2013Q2	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	8892443	USD
CY2012Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	15058163	USD
CY2013Q2	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2134224	USD
CY2012Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	823064	USD
CY2013Q2	halo	Additional Achievement Of Development And Regulatory Milestones AdditionalAchievementOfDevelopmentAndRegulatoryMilestones	84000000	USD
CY2013Q2	halo	Additional Maximum Proceeds Receivable From Partner Of License And Collaborative Agreement Upon Achievement Of Clinical Development Milestones AdditionalMaximumProceedsReceivableFromPartnerOfLicenseAndCollaborativeAgreementUponAchievementOfClinicalDevelopmentMilestones	58500000	USD
	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.04
CY2013Q2	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.02
CY2012Q2	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.02
	halo	Allocated Share Based Compensation Expense Per Share Basic And Diluted AllocatedShareBasedCompensationExpensePerShareBasicAndDiluted	0.04
CY2013Q2	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	194839	USD
CY2012Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	178140	USD
	halo	Available For Sale Securities Sold AvailableForSaleSecuritiesSold	0	USD
CY2012Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	8152602	USD
CY2013Q2	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	8234842	USD
CY2013Q2	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2945954	USD
CY2012Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2274551	USD
CY2012Q1	halo	Public Offering Price Per Share PublicOfferingPricePerShare	10.61
CY2012Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1020000	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	113285582	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC

Files In Submission

Name	View Source	Status
0001483813-13-000085-index-headers.html	Edgar Link	pending
0001483813-13-000085-index.html	Edgar Link	pending
0001483813-13-000085.txt	Edgar Link	pending
0001483813-13-000085-xbrl.zip	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex3111.htm	Edgar Link	pending
ex3121.htm	Edgar Link	pending
ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
halo-20130630.xml	Edgar Link	completed
halo-20130630.xsd	Edgar Link	pending
halo-20130630_cal.xml	Edgar Link	unprocessable
halo-20130630_def.xml	Edgar Link	unprocessable
halo-20130630_lab.xml	Edgar Link	unprocessable
halo-20130630_pre.xml	Edgar Link	unprocessable
halo2q2013-10q.htm	Edgar Link	pending
junepipeline.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2013 Q3 Form 10-Q Financial Statement

#000148381313000085 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2013 Q3 Form 10-Q Financial Statement

#000148381313000085 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo